natgillin/translations-raw huggingface dataset:
It is recommended that live vaccines not be given concurrently with Remicade.
Ne preporučuje se istodobna primjena živih cjepiva s lijekom Remicade.
It is recommended that live vaccines not be given concurrently with Remsima.
Ne preporučuje se istodobna primjena živih cjepiva s lijekom Remsima.
It is recommended that live viral or live bacterial vaccines (such as Bacillus of Calmette and Guérin (BCG)) should not be given concurrently with STELARA.
Preporuka je da se živa virusna ili živa bakterijska cjepiva (kao što je cjepivo Bacillus Calmette- Guérin (BCG)) ne smiju davati istovremeno sa STELAROM.
It is recommended that Mimpara be taken with food or shortly after a meal, as studies have shown that bioavailability of cinacalcet is increased when taken with food (see section 5.2).
Preporučuje se Mimparu uzeti s hranom ili neposredno nakon obroka jer su studije pokazale kako je bioraspoloživost sinakalceta povećana kad se uzima s hranom (vidjeti dio 5.2).
It is recommended that mothers infected by HIV do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Preporučuje se da majke zaražene HIV-om ni u kojem slučaju ne doje kako bi se izbjegao prijenos HIV-a.
It is recommended that no more than three re-treatments should be used during a pregnancy.
Tijekom jedne trudnoće ne preporučuje se primjena više od tri tretmana.
It is recommended that no more than three retreatments should be used during a pregnancy.
Tijekom jedne trudnoće ne preporučuje se više od tri ciklusa liječenja.
It is recommended that no more than three retreatments should be used during a pregnancy.
Tijekom jedne trudnoće ne preporučuje se više od tri tretmana.
It is recommended that NutropinAq be administered using sterile, disposable needles.
Preporučuje se primjenjivati NutropinAq jednokratnim sterilnim iglama.
It is recommended that other medicinal products associated with myopathy should if possible be temporarily discontinued during treatment with Cubicin unless the benefits of concomitant administration outweigh the risk.
Preporučuje se da se drugi lijekovi povezani s miopatijom, ako je moguće, privremeno ukinu tijekom liječenja Cubicinom, osim ako koristi od istodobne primjene ne nadmašuju rizik.
It is recommended that paediatric patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Flixabi therapy.
Prije početka terapije lijekom Flixabi, preporučuje se po mogućnosti cijepiti pedijatrijske bolesnike u skladu s važećim programom cijepljenja.
It is recommended that paediatric patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Inflectra therapy.
Prije početka terapije lijekom Inflectra, preporučuje se po mogućnosti cijepiti pedijatrijske bolesnike u skladu s važećim programom cijepljenja.
It is recommended that paediatric patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Remicade therapy.
Prije početka terapije lijekom Remicade, preporučuje se po mogućnosti cijepiti pedijatrijske bolesnike u skladu s važećim programom cijepljenja.
It is recommended that paediatric patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Remsima therapy.
Prije početka terapije lijekom Remsima, preporučuje se po mogućnosti cijepiti pedijatrijske bolesnike u skladu s važećim programom cijepljenja.
It is recommended that Panretin gel should be applied for an initial treatment period of up to 12 weeks.
U početnom razdoblju liječenja preporučuje se primjenjivati Panretin u trajanju do 12 tjedana.
It is recommended that patients are advised about the possible effects on vision if they take Trobalt with alcohol.
Preporučuje se savjetovati bolesnike o mogućim utjecajima na vid ako uzimaju Trobalt salkoholom.
It is recommended that patients be premedicated to ameliorate the effects of infusion reactions (see section 4.2).
Kako bi se ublažile reakcije povezane s infuzijom, preporučuje se premedikacija bolesnika (vidjeti dio 4.2).
It is recommended that patients continue treatment with trametinib until patients no longer derive benefit or the development of unacceptable toxicity.
Preporučuje se da bolesnici nastave liječenje trametinibom sve dok od njega imaju koristi ili do razvoja neprihvatljive toksičnosti.
It is recommended that patients not be given salicylates for an interval of six weeks after receiving the varicella vaccine.
Preporuča se da se bolesnicima ne daju salicilati u razdoblju od šest tjedana nakon primanja cjepiva protivvaričela.
It is recommended that patients receive 2 cycles of VELCADE following a confirmation of a complete response.
Preporučuje se da bolesnici prime još 2 ciklusa liječenja VELCADEom nakon potvrđenog kompletnog odgovora.
It is recommended that patients receive pre-medication with standard doses of dexamethasone (or an equivalent corticosteroid) together with a 5-HT3 antagonist (or other antiemetic) at least 30 minutes prior to ONIVYDE infusion.
Preporučuje se da bolesnici prime premedikaciju standardnim dozama deksametazona (ili ekvivalentnog kortikosteroida) zajedno sa 5-HT3 antagonistom (ili drugim antiemetikom) najmanje 30 minuta prije primanja infuzije lijeka ONIVYDE.
It is recommended that patients receiving buprenorphine/naloxone should be closely monitored if inducers (e.g. phenobarbital, carbamazepine, phenytoin, rifampicin) are co-administered.
Kod istodobne primjene induktora (npr. fenobarbitala, karbamazepina, fenitoina, rifampicina) preporučuje se pažljivo nadziranje bolesnika koji primaju buprenorfin/nalokson.
It is recommended that patients receiving leflunomide are not treated with colestyramine or activated powdered charcoal because this leads to a rapid and significant decrease in plasma A771726 (the active metaboliteof leflunomide; see also section 5) concentration.
Preporučuje se da se bolesnici koji uzimaju leflunomid ne liječe kolestiraminom ili aktivnim ugljenom u prahu jer oni utječu na brzo i značajno smanjenje koncentracije A771726 (aktivnog metabolita leflunomida; vidjeti dio 5) u plazmi.
It is recommended that patients treated with substances that are metabolised by the CYP3A enzyme system are to be carefully monitored for two weeks at the start of, or after the end of treatment with rufinamide, or after any marked change in the dose.
Preporučuje se pažljivo pratiti bolesnike liječene tvarima koje metabolizira sustav enzima CYP3A4 u razdoblju od dva tjedna nakon početka ili prestanka liječenja rufinamidom ili nakon bilo koje izrazitije promjene doze.
It is recommended that patients treated with substances that are metabolised by the CYP3A4 enzyme system are to be carefully monitored for two weeks at the start of, or after the end of treatment with rufinamide, or after any marked change in the dose.
Preporučuje se pažljivo pratiti bolesnike liječene tvarima koje metabolizira sustav enzima CYP3A4 u razdoblju od dva tjedna nakon početka ili prestanka liječenja rufinamidom ili nakon bilo koje izrazitije promjene doze.
It is recommended that patients undergo baseline radiographic assessment by lung computed tomography scan or chest radiograph prior to the initiation of Torisel therapy.
Preporučuje se radiografski pregled bolesnika tako da se naprave snimke pluća kompjutoriziranom tomografijom ili rendgensko snimanje pluća prije početka terapije Toriselom.
It is recommended that Pegasys pre- filled syringes be used for children and adolescents, as they allow for dose adjustments.
U djece i adolescenata preporučuje se primjena lijeka Pegasys u napunjenim štrcaljkama jer one omogućuju prilagođavanje doze.
It is recommended that product is used not more than twice in one year.
Preporuča se proizvod ne koristiti više od dva puta godišnje.
It is recommended that Rapamune be used with ciclosporin and corticosteroids (other medicines to prevent organ rejection) for two to three months.
Preporuča se da se Rapamune primjenjuje s ciklosporinom i kortikosteroidima (drugim lijekovima za sprječavanje odbacivanja organa) tijekom razdoblja od dva do tri mjeseca.
It is recommended that renal function (creatinine clearance and serum phosphate) is assessed in all patients prior to initiating therapy with tenofovir disoproxil fumarate and that it is also monitored after two to four weeks of treatment, after three months of treatment and every three to six months thereafter in patients without renal risk factors.
Preporučuje se procijeniti funkciju bubrega (klirens kreatinina i fosfat u serumu) u svih pacijenata prije početka terapije tenofovirdizoproksilfumaratom i pratiti nakon dva do četiri tjedna liječenja, nakon tri mjeseca liječenja i svakih tri do šest mjeseci nakon toga u pacijenata bez bubrežnih čimbenika rizika.
It is recommended that Senshio should be taken with food at the same time each day.
Preporučuje se lijek Senshio uzimati s hranom svakog dana u isto vrijeme.
It is recommended that serum ferritin be monitored every month.
Preporučuje se pratiti vrijednost serumskog feritina svaki mjesec.
It is recommended that Stocrin be taken on an empty stomach and without food, preferably at bedtime.
Preporuča se da se Stocrin uzme na prazan želudac i bez hrane, po mogućnosti prije odlaska na počinak.
It is recommended that Stribild is discontinued in patients with creatinine clearance that falls to < 70 mL/min while on treatment unless it is considered that the potential benefit of this combination of antiretroviral agents for the individual patient outweighs the possible risks of continuing with therapy.
Preporučuje se prekinuti liječenje Stribildom u pacijenata s padom klirensa kreatinina na < 70 ml/min tijekom liječenja osim ako se ne smatra da potencijalna korist ove kombinacije retrovirusnih lijekova za pojedine pacijente nadmašuje moguće rizike od nastavka liječenja.
It is recommended that Stribild is not initiated in patients with creatinine clearance < 90 mL/min unless, after review of the available treatment options, it is considered that Stribild is the preferred treatment for the individual patient.
Preporučuje se da se liječenje Stribildom ne započinje u pacijenata s klirensom kreatinina < 90 ml/min, osim ako se nakon pregleda dostupnih mogućnosti liječenja ne smatra da je Stribild preferirano liječenje za pojedinog pacijenta.
It is recommended that subjects who receive a first dose of Pumarix, complete the vaccination course with Pumarix.
Preporučuje se da osobe koje prime prvu dozu cjepiva Pumarix završe cijeli postupak imunizacije s cjepivom Pumarix.
It is recommended that Sustiva be taken on an empty stomach and without food, preferably at bedtime.
Preporuča se da se Sustiva uzme na prazan želudac i bez hrane, po mogućnosti prije odlaska na počinak.
It is recommended that the ANC is measured daily for the first 2 to 3 days of filgrastim administration.
Preporučuje se određivati ABN svakodnevno tijekom prva 2-3 dana primjene filgrastima.
It is recommended that the Caelyx infusion line be connected through the side port of an intravenous infusion of 5% (50 mg/ml) glucose.
Preporučuje se da linija za infuziju lijeka Caelyx bude spojena preko postraničnog otvora na cijevi za intravensku infuziju 5%-tne (50 mg/ml) glukoze.
It is recommended that the capsule be swallowed whole with water.
Preporučuje se kapsulu progutati cijelu s vodom.
It is recommended that the conduct and results of these tests are recorded in the patient alert card.
Preporučuje se provođenje i rezultate tih pretraga upisati u Karticu s upozorenjima za bolesnika.
It is recommended that the conduct of these tests should be recorded in the patient's alert card.
Preporučuje se da se rezultati tih testova zabilježe na karticu s upozorenjima za bolesnike.
It is recommended that the conduct of these tests should be recorded in the patient’s alert card.
Preporučuje se da se te pretrage zabilježe u Kartici s upozorenjima za bolesnika.
It is recommended that the conduct of these tests should be recorded in the patient’s alert card.
Preporučuje se zabilježiti provođenje navedenih testova u Karticu s upozorenjima za bolesnika.
It is recommended that the conduct of these tests should be recorded in the patient’s alert card.
Preporučuje se zabilježiti te pretrage u Kartici s upozorenjima za bolesnika.
It is recommended that the date of the first use be noted on the label.
Preporučuje se da se na naljepnici naznači datum prve uporabe bočice.
It is recommended that the date of the first use from the vial be noted on the label.
Preporučuje se da se na naljepnici naznači datum prve uporabe bočice.
It is recommended that the date of the first use from the vial be noted on the label.
Preporučuje se na naljepnici naznačiti datum prve uporabe bočice.
It is recommended that the diluted Aldurazyme solution be administered to patients using an infusion set equipped with a 0.2 µm in-line filter.
Preporučuje se razrijeđenu otopinu lijeka Aldurazyme primijeniti kroz infuzijski sustav s ugrađenim filtrom od 0,2 µm.
It is recommended that the diluted Naglazyme solution be administered to patients using an infusion set equipped with a 0.2 µm in-line filter.
Preporuča se razrijeđenu otopinu Naglazyme-a dati bolesnicima pomoću infuzijskog seta opremljenog s 0,2 μm „in-line“ filtrom.
It is recommended that the dosage of levodopa is reduced during both the dose escalation and the maintenance treatment with Oprymea, depending on reactions in individual patients (see section 4.5).
Preporučuje se smanjiti dozu levodope za vrijeme postupnog povećanja doze, kao i za vrijeme terapije održavanja lijekom Oprymea, ovisno o reakcijama pojedinog bolesnika (vidjeti dio 4.5).
It is recommended that the dose of levodopa is reduced during both the dose escalation and the maintenance treatment with MIRAPEXIN, depending on reactions in individual patients (see section 4.5).
Preporučuje se smanjiti dozu levodope za vrijeme postupnog povećavanja doze, kao i za vrijeme terapije održavanja MIRAPEXINOM, ovisno o reakcijama pojedinog bolesnika (vidjeti dio 4.5).
It is recommended that the dose of levodopa is reduced during both the dose escalation and the maintenance treatment with MIRAPEXIN, depending on reactions in individual patients (see section 4.5).
Preporučuje se sniziti dozu levodope za vrijeme postupnog povećavanja doze, kao i za vrijeme terapije održavanja MIRAPEXINOM, ovisno o reakcijama pojedinog bolesnika (vidjeti dio 4.5).
It is recommended that the dose of levodopa is reduced during both the dose escalation and the maintenance treatment with Oprymea, depending on reactions in individual patients (see section 4.5).
Preporučuje se sniziti dozu levodope za vrijeme postupnog povećavanja doze, kao i za vrijeme terapije održavanja lijekom Oprymea, ovisno o reakcijama pojedinog bolesnika (vidjeti dio 4.5).
It is recommended that the dose of levodopa is reduced during both the dose escalation and the maintenance treatment with Pramipexole Teva, depending on reactions in individual patients (see section 4.5).
Preporučuje se smanjiti dozu levodope za vrijeme postupnog povećavanja doze, kao i za vrijeme terapije održavanja Pramipeksol Teva, ovisno o reakcijama pojedinog bolesnika (vidjeti dio 4.5).
It is recommended that the dose of levodopa is reduced during both the dose escalation and the maintenance treatment with SIFROL, depending on reactions in individual patients (see section 4.5).
Preporučuje se sniziti dozu levodope za vrijeme postupnog povećavanja doze, kao i za vrijeme terapije održavanja SIFROLOM, ovisno o reakcijama pojedinog bolesnika (vidjeti dio 4.5).
It is recommended that the dosing interval for tenofovir disoproxil 245 mg (as fumarate) is modified in adult patients with creatinine clearance < 50 ml/min or in patients who already have ESRD and require dialysis (see section 4.2).
Preporučuje se prilagoditi interval doziranja za dozu od 245 mg tenofovirdizoproksila (u obliku tenofovirdizoproksilfumarata) u odraslih pacijenata s klirensom kreatinina < 50 ml/min i u pacijenata koji već imaju bolest bubrega u završnoj fazi i trebaju dijalizu (vidjeti dio 4.2).
It is recommended that the first 9 days of treatment will be given to you in a hospital or clinic under the supervision of a doctor or nurse experienced in the use of anti-cancer medicines.
Preporučeno je da se liječenje prvih 9 dana provodi u bolnici ili klinici pod nadzorom liječnika ili medicinske sestre s iskustvom u primjeni antitumorskih lijekova.
It is recommended that the healthcare professional advises the patient or care giver how to use the oral syringes to ensure that the correct volume is administered and that the prescription is given in ml.
Preporučuje se da zdravstveni djelatnik bolesniku ili njegovatelju objasni uporabu štrcaljke za usta kako bi se osigurala primjena ispravnog volumena te da je lijek propisan u ml.
It is recommended that the INR be monitored carefully during treatment with REYATAZ/ritonavir, especially when commencing therapy.
Preporučuje se pažljivo pratiti međunarodni normalizirani omjer (INR) tijekom liječenja lijekom REYATAZ/ritonavirom, osobito na početku terapije.
It is recommended that the international normalised ratio (INR) be monitored upon co-administration and following ceasing treatment with idelalisib.
Preporučuje se pratiti međunarodni normalizirani omjer (INR) pri istovremenoj primjeni i nakon prestanka liječenja idelalisibom.
It is recommended that the international normalised ratio (INR) be monitored when warfarin is combined with INTELENCE.
Preporučuje se pratiti međunarodni omjer normalizacije (INR) kada se varfarin kombinira s INTELENCEom.
It is recommended that the lipid profiles be determined before initiating treatment with Tasigna, assessed at month 3 and 6 after initiating therapy and at least yearly during chronic therapy (see section 4.2).
Preporučuje se odrediti profil lipida prije početka liječenja Tasignom, procijeniti ga u 3. i 6. mjesecu nakon početka terapije te najmanje jedanput godišnje tijekom kronične terapije (vidjeti dio 4.2).
It is recommended that the oral daily dose of Envarsus is administered once daily.
Preporučuje se primjena dnevne peroralne doze Envarsusa jedanput na dan.
It is recommended that the patient’s head is in upright position when administrating Instanyl.
Preporučuje se da pri primjeni Instanyla bolesnik uspravno sjedi ili stoji.
It is recommended that the patient’s liver be checked before starting treatment with Suboxone and should also be monitored regularly during treatment.
Preporučuje se da se jetra bolesnika pregleda prije početka terapije lijekom Suboxone te se treba redovito kontrolirati tijekom terapije.
It is recommended that the product information (SmPC and PL) for all formulations is revised to reflect the current knowledge on Osteonecrosis of the jaw (ONJ) and to optimize risk minimisation.
Preporučuje se da se informacije o lijeku (Sažetak opisa svojstava lijeka i Uputa o lijeku) za sve formulacije izmijene kako bi se uvrstila trenutna saznanja o osteonekrozi čeljusti i optimizirala minimizacija rizika.
It is recommended that the product is used immediately after dilution, due to a possible risk for microbial contamination.
Zbog mogućeg rizika od mikrobiološkog onečišćenja, preporučuje se da lijek upotrijebite odmah nakon razrjeđivanja.
It is recommended that the product once diluted be used immediately (see point 5 of this leaflet ‘How to store Bondronat’).
Preporučuje se da se lijek upotrijebi odmah nakon razrjeđivanja (vidjeti dio 5. ove upute o lijeku, “Kako čuvati Bondronat”).
It is recommended that the product once diluted be used immediately (see point 5 of this leaflet ‘How to store Iasibon’).
Preporučuje se da se lijek upotrijebi odmah nakon razrjeđivanja (pogledajte dio 5. ove upute o lijeku, “Kako čuvati Iasibon”).
It is recommended that the product once diluted be used immediately (see point 5 of this leaflet ‘How to store Ibandronic Acid Accord’).
Preporučuje se da se lijek upotrijebi odmah nakon pripreme za primjenu (vidjeti dio 5 ove upute o lijeku, “Kako čuvati Ibandronic acid Accord”).
It is recommended that the reconstitution of the liposomal suspension should be performed in a laminar flow cabinet utilising sterile gloves using aseptic technique.
Preporučuje se da se rekonstituciju liposomalne suspenzije treba izvoditi u kabinetu s laminarnim protokom zraka uz primjenu sterilnih rukavica i aseptičkog postupka.
It is recommended that the Trobalt dose is reduced over a period of at least 3 weeks, unless safety concerns require an abrupt withdrawal (see section 4.2).
Preporučuje se smanjivati dozu lijeka Trobalt tijekom razdoblja od najmanje 3 tjedna, osim u slučaju kada je nagli prekid nužan zbog sigurnosnih razloga (vidjeti dio 4.2).
It is recommended that the vaccine be administered immediately after reconstitution to minimize loss of potency.
Preporučuje se cjepivo primijeniti odmah nakon rekonstitucije, kako bi se smanjila mogućnost gubitka djelotvornosti.
It is recommended that the vaccine be administered immediately after reconstitution, to minimize loss of potency.
Preporučuje se primijeniti cjepivo odmah nakon rekonstitucije kako bi se gubitak potentnosti smanjio na najmanju moguću mjeru.
It is recommended that the vaccine be administered immediately after reconstitution, to minimize loss of potency.
Preporučuje se primijeniti cjepivo odmah nakon rekonstitucije, kako bi se smanjila mogućnost gubitka djelotvornosti.
It is recommended that therapeutic infectious agents not be given concurrently with Inflectra.
Ne preporučuje se primjenjivati terapijske infektivne agense istodobno s lijekom Inflectra.
It is recommended that therapeutic infectious agents not be given concurrently with Remsima (see section 4.4).
Ne preporučuje se istodobna primjena terapijskih infektivnih agenasa istodobno s lijekom Remsima (vidjeti dio 4.4).
It is recommended that therapeutic infectious agents not be given concurrently with Remsima.
Ne preporučuje se primjenjivati terapijske infektivne agense istodobno s lijekom Remsima.
It is recommended that therapeutic infectious agents not be given concurrently with Simponi.
Ne preporučuje se primjenjivati terapijske infektivne agense istodobno s lijekom Simponi.
It is recommended that treatment be continued until disease progression or until unacceptable toxicity has occurred.
Preporučuje se nastaviti liječenje do progresije bolesti ili pojave neprihvatljive toksičnosti.
It is recommended that treatment be continued until progression of the underlying disease.
Preporučuje se nastaviti liječenje do progresije osnovne bolesti.
It is recommended that treatment for such reactions include hydrocortisone administered by intravenous bolus, and epinephrine administered by intravenous bolus once every 3–5 minutes as necessary according to clinical response.
Preporučuje se da liječenje takvih reakcija uključuje hidrokortizon primijenjen intravenskim bolusom i epinefrin primijenjen intravenskim bolusom jednom svakih 3 do 5 minuta po potrebi prema kliničkom odgovoru.
It is recommended that treatment is started with abacavir, lamivudine, and zidovudine separately for the first 6-8 weeks (see section 4.4).
Preporučuje se započeti liječenje s odvojenim abakavirom, lamivudinom i zidovudinom tijekom prvih 6-8 tjedana (vidjeti dio 4.4).
It is recommended that treatment with trastuzumab emtansine be permanently discontinued in patients who are diagnosed with ILD or pneumonitis.
Preporučuje se trajno prekinuti liječenje trastuzumab emtanzinom u bolesnika u kojih se dijagnosticiraju intersticijska bolest pluća ili pneumonitis.
It is recommended that two tablets should be placed in each side of the mouth.
Preporučuje se da se po dvije tablete stave u svaku stranui usta.
It is recommended that vaccinees who received the first dose of IXIARO complete the primary 2-dose vaccination course with IXIARO.
Preporučuje se da osobe koje su primile prvu dozu cjepiva IXIARO primarno cijepljenje završe tako da i 2. doza bude cjepivo IXIARO.
It is recommended that when Inflectra is prepared for infusion, it is used as soon as possible (within 3 hours).
Preporučuje se pripremljenu otopinu za infuziju lijeka Inflectra upotrijebiti što prije (u roku od 3 sata).